ETF · iShares
BTEE iShares NASDAQ US Biotechnology UCITS ETF Dist
ISIN IE00BDZVHG35London Stock Exchange: BTEEBlackRock, Inc.
- Healthcare
- ETF
- ISA
- SIPP
- Distributing
Latest close
LSE$10.39
on
- Ongoing charge
- 0.35% a year
- Fund size
- £59.7m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, BTEE (iShares NASDAQ US Biotechnology UCITS ETF Dist, ISIN IE00BDZVHG35) closed at $10.39 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 13/11/2026 its total return was +57.5%, or +23.0% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +34.0%
- +29.2% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +86.5%
- +68.5% after inflation (UK CPIH)
- 5 years to 13/11/2026
- +57.5%
- +23.0% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,575 on 13/11/2026 — about £1,230 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF Dist in pounds (price only, income paid out not included): 2022 −1.7%, 2023 −0.3%, 2024 +1.7%, 2025 +20.3%; 2026 to 13/11/2026 +27.9%. Returns of iShares NASDAQ US Biotechnology UCITS ETF Dist in pounds (price only, income paid out not included) over the 12 months to 30/09/2026: +42.8%; to 30/09/2025: +5.8%; to 30/09/2024: +10.2%; to 30/09/2023: −7.0%; to 30/09/2022: −5.0%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +27.9% | +23.8% | |
| to | +20.3% | +16.2% | |
| to | +1.7% | −1.8% | |
| −0.3% | −4.3% | ||
| −1.7% | −10.0% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +42.8% | +37.7% |
| from | +5.8% | +1.6% |
| from | +10.2% | +7.4% |
| from | −7.0% | −12.6% |
| from | −5.0% | −12.7% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
19.0%over 5 years
| 1 year | 18.9% |
|---|---|
| 3 years | 19.1% |
| 5 years | 19.0% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since November 2021
- −23.7%
- From to
- Lowest 12-month return
- −22.0%
- 12 months to
- Highest 12-month return
- +60.0%
- 12 months to
- Below its highest weekly close since November 2021
- 1.0%
- High of , latest
In words: Volatility of iShares NASDAQ US Biotechnology UCITS ETF Dist in pounds, annualised from weekly returns to 13/11/2026: 18.9% over 1 year, 19.1% over 3 years, 19.0% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF Dist since November 2021, in pounds: −23.7% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF Dist in pounds (price only, income paid out not included) since January 2021 was −22.0% (12 months to 18/02/2022); the highest was +60.0% (12 months to 03/07/2026). On 13/11/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF Dist was 1.0% below its highest weekly close since November 2021 (30/10/2026), in pounds.
As of , price only — income paid out is not included
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.35%
- a year
- On £10,000
- £35
- a year, roughly
- Over five years
- £174
- of £10,000, before growth
- 14 charge less
- 3 the same
- 11 charge more
Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF Dist 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
iShares NASDAQ US Biotechnology UCITS ETF Dist is an exchange-traded fund (ETF) from iShares, launched in 2018.
It tracks the NASDAQ / Biotechnology.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is paid out to holders as cash, usually a few times a year.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- BTEE
- ISIN
- IE00BDZVHG35
- Provider
- iShares
- Tracks
- NASDAQ / Biotechnology
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Distributing, paid semi-annual
- Income is paid out to holders as cash, usually a few times a year.
- Ongoing charge
- 0.35% a year · about £35 on £10,000
- Fund size
- £59.7m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- USD
- Category
- Healthcare
Price chart
Over the last year, the closing price went from $8.06 on 14/11/2025 to $10.39 on 13/11/2026 (+28.9%). The lowest close shown was $8.06 on 14/11/2025 and the highest $10.62 on 30/10/2026.
One close a week. Before 31/07/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded. Price only — income paid out is not included, so the line can end below the total return above.
As of , at least 15 min delayed
Five years of prices, and after inflation
262 weekly closes, from 12/11/2021 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 244
- 250 reported in all
- Ten largest
- 48.5%
- of the whole fund
- Effective number of holdings
- 29
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 9.0%
- Gilead Sciences
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Gilead SciencesGILDHealth Care | 8.96% |
| 2 | AmgenAMGNHealth Care | 8.40% |
| 3 | Vertex PharmaceuticalsVRTXHealth Care | 7.88% |
| 4 | ModernaMRNAHealth Care | 6.52% |
| 5 | Regeneron PharmaceuticalsREGNHealth Care | 5.88% |
| 6 | Revolution MedicinesRVMDHealth Care | 2.65% |
| 7 | BiogenBIIBHealth Care | 2.36% |
| 8 | IlluminaILMNHealth Care | 2.07% |
| 9 | Royalty Pharma · Class ARPRXHealth Care | 1.93% |
| 10 | Roivant SciencesROIVHealth Care | 1.81% |
As of , holdings as published
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.
By sector
- Health Care99.9%
- Cash and derivatives0.1%
By type of asset
- Equity99.9%
- Cash and money market0.1%
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 100 largest and what changed since .
More of the portfolio
The fund publishes 250 holdings; the ten largest make up 48.5% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Funds tracking the same index
3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (13/11/2026).
| Fund | Charge | 1 year | 3 years | 5 years |
|---|---|---|---|---|
| Invesco NASDAQ Biotech UCITS ETFAccumulating · 0.40% a year | 0.40% | +33.3% | +86.5% | +57.3% |
| iShares NASDAQ US Biotechnology UCITS ETFAccumulating · 0.35% a year | 0.35% | +33.2% | +86.4% | +57.1% |
| iShares NASDAQ US Biotechnology UCITS ETF DistThis fundDistributing · 0.35% a year | 0.35% | +34.0% | +86.5% | +57.5% |
As of
Nasdaq Biotechnology funds compared: charges, sizes and share classes
Read more:Index fundsTracking differenceHow funds are compared
Other versions of this fund
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1, 3 and 5 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 254 rolling 12-month returns since January 2021, and of 150 rolling three-year returns, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 3 largest falls since November 2021, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Moves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core S&P 500 UCITS ETF, over the three years to 13/11/2026 (154 weeks).
Pro
Pro — currently by invitation
Pro includes moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of BTEE?
The ongoing charge of BTEE is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF Dist 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
What does BTEE track?
BTEE tracks the NASDAQ / Biotechnology.
Is BTEE accumulating or distributing?
BTEE is distributing: income is paid out to holders as cash, usually a few times a year. It pays out semi-annual.
What is the ISIN of BTEE?
The ISIN of BTEE is IE00BDZVHG35. An ISIN identifies one exact share class of a fund; BTEE is its ticker on the London Stock Exchange.
What does BTEE hold?
As of 06/11/2026, BTEE holds 250 positions, according to its published holdings. The largest is Gilead Sciences at 8.96% of the fund; the ten largest make up 48.5%. Its ten largest holdings are Gilead Sciences (8.96%), Amgen (8.40%), Vertex Pharmaceuticals (7.88%), Moderna (6.52%), Regeneron Pharmaceuticals (5.88%), Revolution Medicines (2.65%), Biogen (2.36%), Illumina (2.07%), Royalty Pharma · Class A (1.93%) and Roivant Sciences (1.81%).
What were BTEE’s returns in each of the last five years?
Calendar-year returns of BTEE in pounds (price only, income paid out not included): 2022 −1.7%, 2023 −0.3%, 2024 +1.7%, 2025 +20.3%; 2026 to 13/11/2026 +27.9%. Past performance is not a guide to future returns.
How has BTEE done after inflation?
Over the five years to 13/11/2026 BTEE’s total return was +57.5%, or +23.0% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
- Fund documents
- Fund page at iShares · Key investor information document (KIID) · Factsheet (links checked )
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.